Trevena (NASDAQ: TRVN) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Trevena to similar businesses based on the strength of its profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.
Earnings & Valuation
This table compares Trevena and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Trevena||$3.75 million||-$102.99 million||-1.05|
|Trevena Competitors||$290.27 million||$35.99 million||57.53|
This table compares Trevena and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
56.1% of Trevena shares are held by institutional investors. Comparatively, 49.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.6% of Trevena shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Trevena has a beta of -0.58, indicating that its share price is 158% less volatile than the S&P 500. Comparatively, Trevena’s rivals have a beta of 2.80, indicating that their average share price is 180% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Trevena and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trevena currently has a consensus target price of $8.65, suggesting a potential upside of 400.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.85%. Given Trevena’s stronger consensus rating and higher possible upside, equities analysts clearly believe Trevena is more favorable than its rivals.
Trevena rivals beat Trevena on 7 of the 13 factors compared.
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.